| ABBV |
Report |
Adjusted operating EPS |
IN-LINE |
pred ~$3.64 vs. cons $3.61 |
MEDIUM |
| ABBV |
Report |
Skyrizi revenue |
BEAT |
pred ~$5.510B vs. cons $5.443B |
MEDIUM |
| ABBV |
Report |
Neuroscience revenue |
BEAT |
pred ~$3.150B vs. cons $3.116B |
MEDIUM |
| ABBV |
Guide |
FY 2026 adjusted EPS |
UNCHANGED |
guide ~$13.91-$14.11 vs. cons $14.09 |
MEDIUM |
| ABBV |
Guide |
FY 2026 net revenue |
UNCHANGED |
guide ~$67.3B vs. cons $67.38B |
MEDIUM |
| ABBV |
Guide |
Q3 2026 adjusted EPS |
UNCHANGED |
guide ~$3.84-$3.88 vs. cons $3.85 |
LOW |
| ABBV |
Guide |
FY 2026 Skyrizi demand tone |
BETTER |
continued IBD/share-gain strength; consensus UNVERIFIED |
LOW |
| ABBV |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| ABBV |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — implicit Q4 estimate risk |
LOW |